Cronos (CRON) stock spent most of last year underwater from its IPO price. Of course, after Altria announced a $1.

You know there was some bad news with a company’s quarterly update when the stock tanks after the results are announced. That’s what …

With Intercept (ICPT) preparing to release Phase 3 results from its REGENERATE study in Non-Alcoholic Steatohepatitis (NASH) patients, Gilead (GILD) announced yesterday that its top late-stage NASH drug …

It’s a very rewarding trading day for investors in MacroGenics (MGNX) with shares up over 120%, making the stock Wall Street’s bull of …

Shares of Trevena (TRVN) came back to life. The struggling biotech stock took a rare leap upward last week, as well as today, as resolution …

Congrats. Evolus (EOLS) is the first company to win FDA approval for a neurotoxin that is considered biosimilar to branded Botox for the …

The turnaround at Teva Pharmaceutical Industries (TEVA) remains on schedule. Investors appear satisfied that CEO Kare Schultz is making enough progress in battling …

Amarin’s (AMRN) Vascepa is currently approved to treat around 3.8 million Americans with high triglycerides, as an adjunct to diet.

Investors love healthcare stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Shares of …

Year-to-date, Amarin (AMRN) stock is up nearly 20% due to Pfizer buyout chatter. According to rumors, the pharma giant is interested in making …